Users can learn about advanced therapies that may help with appetite control, metabolism, and weight management goals
Locally Owned & Patient-Centered: As a locally owned practice, we prioritize your long-term success over corporate quotas
If approved for obesity in April 2026, orforglipron would initially be marketed under a single indication, with the diabetes indication expected to follow approximately 12-18 months later
However, at this stage, following comparison of what is available with minimal data sets, consideration is normally given to further searching, further requests for information to industry, and the use of modelling or default values to fill data gaps
The truth: research on smell and GLP-1s is still limited
10.3810/pgm.2013.05.2659 123